ESMO 2021: CheckMate 204 Update Confirms First-Line Use of Nivolumab-Ipilimumab for Advanced Melanoma With Asymptomatic Brain Metastases
A few patients with symptomatic brain metastases also benefited, even if taking steroids
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.